# Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

> **NCT06375161** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Tongji Hospital, Tongji University School of Medicine** · enrollment: 12 (estimated)

## Conditions studied

- B Cell Malignancies

## Interventions

- **BIOLOGICAL:** anti-CD19-CAR-T cells

## Key facts

- **NCT ID:** NCT06375161
- **Lead sponsor:** Shanghai Tongji Hospital, Tongji University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-11
- **Primary completion:** 2025-12-10
- **Final completion:** 2039-12-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375161, "Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06375161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*